REPL
Replimune Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 4
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About REPL
Replimune Group, Inc.
A company that developing oncolytic immunotherapy for the treatment of solid tumor types
500 Unicorn Park Drive, Suite 303, Woburn MA 01801
--
Replimune Group, Inc., was incorporated in Delaware in 2015. The company is a clinical-stage biotechnology company dedicated to applying their leading expertise in oncolytic immunotherapy to transform the lives of cancer patients. Use the company's proprietary Immulytic platform to design and develop product candidates designed to maximize the activation of the immune system against cancer.
Company Financials
EPS
REPL has released its 2026 Q2 earnings. EPS was reported at -0.9, versus the expected -0.79, missing expectations. The chart below visualizes how REPL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
